Long-Acting Glatiramer Acetate Depot Under Review for Relapsing MS
The FDA has accepted for review the NDA for glatiramer acetate depot 40 mg for the treatment of relapsing forms of multiple sclerosis.
Source: neurologyadvisor.com
Page 3 - Mapi Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mapi Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mapi Pharma Today - Breaking & Trending Today
Cough-assisted Devices Global Market to Register Incremental Growth at a CAGR of ~7% by 2028
/PRNewswire/ -- DelveInsight's Cough-assisted Devices Market Insights report provides the current and forecast market analysis, individual leading...
Source: prnewswire.com
:max_bytes(150000):strip_icc()/k53KU-s-p-500-biggest-gains-and-losses-2023-08-07T164950.533-886e506c956345668dcafa65df7af8b5.png)
S&P 500 Gains and Losses Today: Stocks Take Off After Earnings Reports
The S&P 500 snapped a four-day losing streak on Monday, Aug. 7, 2023, rising 0.9% after the latest round of earnings reports.
Source: investopedia.com
![Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] - Vimarsana News](https://www.marketscreener.com/images/twitter_MS_fdblanc.png)
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
$ Free Cash Flow $2,300 - $2,700 ___________ Includes the full year expected performance for the planned divestitures and excludes any potential related costs, such as taxes and transaction costs,...
Source: marketscreener.com
Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing and...
Source: marketscreener.com